PDL therapy fails endpoints in Phase III

PDL BioPharma says its late-stage trial of an experimental therapy for advanced liver disease failed to meet its primary endpoints. The study evaluated the efficacy of terlipressin on kidney function and survival in patients with Type 1 hepatorenal syndrome. While researchers found positive trends in the data, the results failed to measure up to the statistical significance that was sought. PDL says now that it will discuss the future of the drug with its collaborator, Orphan Therapeutics, before deciding how to proceed. PDL's second-quarter net loss, meanwhile, widened from the year before.

- here's the report on PDL from MarketWatch